InvestSMART

Clarity Pharmaceuticals Ltd (ASX:CU6)

ALERT: Price-sensitive ASX Announcement for CU6
Current share price for CU6 : $2.320 -0.02 (-0.85%)+
Announcement
Release
13 Jun 2025 9:58AM
Price at Release
$2.340
Full Release
download
Summary
Clarity Pharmaceuticals Ltd announced topline results from the SABRE clinical trial of its product candidate, 64Cu-SAR-bisPSMA (CU6), for the diagnosis of prostate cancer. The trial met its primary and key secondary endpoints, demonstrating safety and performance in imaging prostate-specific membrane antigen (PSMA) positive lesions in men with biochemical recurrence (BCR) of prostate cancer. CU6 showed high sensitivity, favorable safety profile, and potential for widespread clinical adoption. The SABRE results support further clinical development and regulatory submissions for CU6, marking a significant milestone for Clarity Pharmaceuticals’ diagnostic pipeline.
Key Points
  • Clarity Pharmaceuticals announced topline results from the SABRE trial for 64Cu-SAR-bisPSMA (CU6).
  • The SABRE trial focused on men with biochemical recurrence (BCR) of prostate cancer.
  • Primary endpoint was met: safety and detection of PSMA-positive lesions.
  • Key secondary endpoint of sensitivity was also achieved.
  • CU6 demonstrated favorable safety profile with no serious adverse events related to the product.
  • High sensitivity and clear imaging of prostate cancer recurrence were demonstrated.
  • Results support further clinical development and regulatory submissions.
  • CU6 offers potential benefits in logistics and broader clinical adoption due to copper-64's longer half-life.
  • Clarity’s proprietary Targeted Copper Theranostics platform underpins the development of CU6.
  • The SABRE study results represent a significant milestone for Clarity Pharmaceuticals’ diagnostic product pipeline.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.